In 2011, The CFIDS Association brought together a group of leaders in the field of ME/CFS to help direct our research efforts. Recently we invited additional members to our Research Advisory Council; people with expertise in regulatory, intellectual property, legal and privacy issues. Since this required people in addition to scientists, we changed the designation from Scientific Advisory Board to Research Advisory Council (RAC).
The Research Advisory Council will help guide and shape our research road-map and regulatory framework for ME/CFS as related to our 3-year strategic plan. Like its predecessor, the RAC is a volunteer advisory group, and it will not evaluate or approve grant proposals. The group will meet 2 to 4 times a year, in addition to individual consultations – the first in-person meeting between the RAC, staff and Board of Directors is planned for March 2014 at Banbury/Cold Spring Harbor.
We are honored to have the benefit of diverse expertise from these esteemed experts representing a variety of scientific and strategic disciplines. The backgrounds and qualifications of our advisors help ensure the strength of our program.
Italo Biaggioni, M.D.
Professor of Medicine, Professor of Pharmacology, Vanderbilt University
Dr. Biaggioni’s basic research focuses on the clinical and molecular pharmacology of adenosine, and its role in normal physiology and disease states. His clinical research focuses on the interaction between neural (autonomic) and metabolic (adenosine, nitric oxide) mechanisms that regulate blood pressure. Their goal is to define the role of the autonomic nervous system in blood pressure disorders to develop targeted therapies.
Dr. Biaggioni leads one of a handful of national referral centers for the evaluation of patients with disorders of the autonomic nervous system. These include patients with various forms of orthostatic hypotension (pure autonomic failure and multiple system atrophy-Shy Drager syndrome), orthostatic intolerance (POTS, mitral valve prolapse syndrome), syncope, and autonomic forms of hypertension (paroxysmal hypertension, baroreflex failure). They run a complete autonomic laboratory that includes autonomic reflex testing, tilt table testing, microneurography (direct recording of sympathetic traffic), measurement of plasma catecholamines and metabolites, and estimation of norepinephrine spillover.
Dr Biaggioni has served as a scientific advisor to the CFIDS Association of America since 2011.
Gordon Broderick, Ph.D.
Professor, Center for Psychological Studies, Nova Southeastern University
An engineer by training, Dr. Broderick holds a doctorate in chemical engineering from the University of Montreal as well as a Master’s in chemical engineering and an undergraduate in mechanical engineering both from McGill University.
After 12 years in private sector research, he joined the Institute for Biomolecular Design (University of Alberta) in 2002 to lead the CyberCell computational team in creating a dynamic spatial model of a living cell. Building on this study of complex emergent behavior in biology Dr. Broderick’s current research efforts are focused on understanding immune dysfunction and autoimmunity from an integrated systems perspective. In particular his group is investigating how subtle imbalances in the interplay between the immune system’s multiple components as well as its interactions with the endocrine and nervous systems may lead to complex disorders such as Gulf War Illness and chronic fatigue syndrome (CFS).
Dr. Broderick recently moved his research from the University of Alberta to join Dr. Nancy Klimas in launching Nova Southeastern University’s new Institute for Neuro-immune Medicine (INIM). This new institute brings together a cross disciplinary team of researchers from the computational, clinical and basic life sciences with the goal of developing immune and hormone-based therapies for ME/CFS, Gulf war Illness and like illnesses that are both safe and effective.
Dr. Broderick has served as a scientific advisor to the CFIDS Association of America since 2011.
Russell “Rusty” Bromley
Principal, TRAC Consulting
Mr. Bromley is founded Translational Research Acceleration Consulting (TRAC) in 2010 to assist non-profit medical research organizations in creating new, more effective business models for accelerating the discovery and development of new treatments and cures. TRAC Consulting specializes in designing and implementing strategic research plans, and collaborative operational models, that are aligned with an organization’s mission and the unmet medical needs of patients. Prior to founding TRAC Consulting, he served for seven years as the Chief Operating Officer of the Myelin Repair Foundation where he was instrumental in the creation, implementation and evolution of the of their Accelerated Research Collaboration business mode, strategic research plan, identification and protection of resulting intellectual property, and development of relationships with a broad range of academic and commercial organizations. Mr. Bromley also serves as the Chairman of the Board of Vascular Cures, a foundation dedicated to ending death and disability from vascular disease.
Mr. Bromley brings a unique combination of business experience in both academic and commercial research environments. His expertise includes the creation and protection of innovative technologies, business development, and marketing strategy for high tech and life science companies. Formerly he was CEO of LabVelocity, Inc., an Internet information portal for the life science research community. Prior to that, he was CEO of Berkshire Holding Corporation, a privately held, multinational manufacturing company and spent 17 years with American Hospital Supply Corporation and Baxter Healthcare, in both the distribution and diagnostics businesses, culminating with seven years a President of the Burdick and Jackson division. Mr. Bromley holds a degree in Biochemistry from Rice University.
Mr. Bromley has served as a scientific advisor to the CFIDS Association of America since 2011.
Paul R. DeStefano, J.D.
Partner, McDermott Will & Emery LLP
Paul R. DeStefano is a partner in the law firm of McDermott Will & Emery LLP and is based in the Firm’s Silicon Valley office. He is a member of the Firm’s Health Industry group, and the Firm’s Life Sciences & Medical Devices group.
Paul specializes in strategic planning related to the formation, finance and operations of start-up companies in the biotech industry. He has represented U.S. companies in raising over $3 billion through strategic alliances with larger foreign collaborators and regularly acts on behalf of Japanese, German, British, French and Swiss entities in their investments in U.S. equity and intellectual property. He further represents a number of foreign companies on their investments and intellectual property in the United States.
Paul has represented U.S. start-ups in raising over $250 million from the venture capital community and has been involved as counsel in over 50 IPOs. He has served as an advisor to a number of foreign investment banks and funds with respect to potential investments in the United States and regularly sits as an expert witness with respect to the valuation of intellectual property.
Paul is a former chief legal officer of Genentech, Inc., having served in that capacity for six years, two of them on the company’s management committee. He was also involved as counsel in raising over $300 million in “strategic alliances” and over $200 million in R&D limited partnerships.
Paul has been a lecturer at Santa Clara University School of Law, Stanford Law School, U.C. Berkeley School of Law, Dickinson School of Law and University of San Francisco School of Law, and a visiting professor of philosophy at Dickinson College.
Paul has served as an advisor to the Robert Woods Johnson Foundation and National Academy of Sciences on the commercialization of human gene therapy. He has also acted as an advisor to the Institute of Medicine, National Academy of Sciences on vaccine liability issues. Paul was appointed to the California AIDS vaccine advisory panel by the governor of California and invited as a witness before the Presidential Commission on the Human Immunodeficiency Virus Epidemic. He served as an advisor to the Scottish Development Agency and the Weizmann Institute of Israel on the commercialization of local-origin technologies, and as a consultant to the Conservation Foundation and United Nations Human Settlements Convention. In 2012, Paul was selected as a Life Science Star by LMG Life Sciences.
Paul speaks and writes regularly on legal and technology issues, particularly those related to the biological sciences. He is admitted to practice in California and before the U.S. District Court for the Northern District of California.
Mr. Bromley has served as a scientific advisor to the CFIDS Association of America since 2011.
Roger Y. Dodd, Ph.D.
Vice President, Research and Development and Director, American Red Cross, Holland Laboratory
Roger Dodd was born in England and obtained his BSc in biochemistry at the University of Sheffield in 1964. He worked as a Scientific Officer in the Ministry of Defence (UK) for about six years and in 1970 left for the United States to join the American Red Cross, where he has worked for the past 42 years. He rapidly developed his research interest in transfusion-transmitted infections. During that time, he obtained his PhD in Microbiology at the George Washington University in 1978. He is currently Vice President, Research and Development, and Director of the Holland Laboratory and is responsible for the Red Cross research programs supporting its blood program. He has more than 175 publications and has edited three books on transfusion transmitted infections. He has been an Advisor to WHO and he serves on the Editorial Boards of Transfusion, Transfusion Medicine and Transfusion Medicine Reviews and is a Past President of the AABB (formerly American Association of Blood Banks). He was elected to the position of Vice President on the ISBT Board in 2010. He has served as Chair of the Global Collaboration on Blood Safety. He has received the Morten Grove-Rasmussen and Emily Cooley Memorial Awards from the AABB, a Tiffany Award from the American Red Cross, and the John Snow award from the American Public Health Association.
Dr. Dodd has served as a scientific advisor to the CFIDS Association of America since 2011.
Mark A. Demitrack, M.D.
Vice President and Chief Medical Officer, Neuronetics, Inc.
Mark A. Demitrack, MD is Vice President and Chief Medical Officer of Neuronetics, in Malvern, PA. Dr. Demitrack is a board-certified psychiatrist with over twenty years of experience in both academic and industry settings in clinical research of mood disorders and related conditions. At Neuronetics, he designed and supervised the clinical development program for the NeuroStar TMS Therapy System, which received FDA clearance in October, 2008 for the treatment of patients with pharmacoresistant major depression. Prior to joining Neuronetics, Dr. Demitrack was Assistant Vice President for Global Medical Affairs in Neuroscience at Wyeth Pharmaceuticals where he was responsible for post-marketing clinical development of the Effexor XR brand. Dr. Demitrack also served as Medical Director of the New Antidepressant Team at Lilly Research Laboratories where he led the registration clinical development and the NDA submission program for the novel antidepressant, duloxetine (Cymbalta). Prior to his tenure in private industry, Dr. Demitrack was on the faculty of the Department of Psychiatry at the University of Michigan Medical School, where he was Director of the Michigan Eating Disorders Program and received federal grant funding in clinical research activities studying the neuroendocrine pathophysiology of eating disorders and also chronic fatigue syndrome and fibromyalgia. Dr. Demitrack received a BA in Physics from Columbia University, and his MD degree from the Robert Wood Johnson Medical School in New Jersey. He pursued his psychiatry residency training at the University of California-San Francisco and completed a research fellowship in clinical neuroendocrinology at the National Institute of Mental Health. Dr. Demitrack has published over 100 articles, book chapters and reviews on the pathophysiology and treatment of mood disorders and related conditions.
K. Kimberly McCleary
Patient-Centered Research Advocate and Consultant
As president & CEO of the CFIDS Association from 1991 until June 2013, Kim McCleary established her credentials and earned a reputation as an articulate patient advocate, a keen policy strategist, a diplomatic bridge builder and a dedicated servant leader. Kim has met with thousands of patients and their loved ones, scientists, legislators, public health officials, health care professionals and journalists; she has made scores of presentations at workshops and conferences and has written many articles about a wide range of research, policy and education issues. Kim has testified before Congress, has been featured in television, radio and print interviews as a leading authority on ME/CFS (also known as chronic fatigue syndrome or CFS) and has served on many expert committees for private and public institutions.
In the mid-1990s, Kim was instrumental in uncovering $12.9 million in misspending by the U.S. Centers for Disease Control & Prevention for its CFS program and she worked with the agency and members of Congress to restore those funds to research and awareness activities. She helped develop a 1998 policy ruling from the Social Security Administration that first recognized CFS as a disabling condition and she fought to create and sustain a dedicated federal advisory committee to the Secretary of Health and Human Services on ME/CFS research and education. She helped found the Chronic Pain Research Alliance and joined with other leaders and Pfizer to establish the Campaign to End Women’s Pain in 2010. In 2012, Kim led the CFIDS Association of America’s launch of its Research Institute Without Walls and the Partnering to End Pain project selected by Sanofi U.S. as a finalist in the company’s Collaborate | Activate Innovation Challenge. Kim has participated in every opportunity organized by the FDA to shape its new Patient-Focused Drug Development Initiative, including the Process Consultation meeting series and a range of consultative opportunities leading up the first of the 20 PFDDI workshops focused on CFS and ME held April 25, 2013.
Kim recently relocated to Washington, D.C., and is now providing consulting services to several advocacy organizations. She is a member of the international Association of Fundraising Professionals and FasterCures’ advisory board to The Research Acceleration and Innovation Network (TRAIN). She is a graduate of the University of North Carolina at Chapel Hill, a native of upstate New York, a wife and mother of two young adults. She was honored by Redbook magazine as a “Mother and Shaker” in healthcare along with then-Senator Hillary Rodham Clinton and (now) Surgeon General Dr. Regina Benjamin. She has received numerous other awards and formal recognitions for her work.
Kelly Morren, B.S.
Global Director, ServiceSource International
Ms. Morren is Global Director for ServiceSource International, based in Denver, CO. Her work focuses on the strategy, planning and leadership of complex transitions, balancing strategic, financial and tactical perspectives.
Her areas of expertise include innovative strategy, customer engagement process, change management, sigma based process development/reengineering, cross-cultural/diverse team collaboration and major transition project management. She has more than 20 years’ experience in the Americas, Europe and Asia Pacific. Prior to joining ServiceSource International, Ms. Morren was principal owner of Integrated Strategy and was a customer relationship manager for Sun Microsystems Inc. She has lived and worked abroad in London and Taipei.
Ms. Morren has served as a scientific advisor to the CFIDS Association of America since 2011.
Bernard Munos is the founder of InnoThink, a consultancy that focuses on innovation, and helps biomedical research organizations become better innovators. Before that, he served as an advisor for corporate strategy at Eli Lilly, where he focused on disruptive innovation and the radical redesign of R&D. He is a Senior Fellow at FasterCures, a center of the Milken Institute, a member of the Advisory Council and Cures Acceleration Network Review Board of NIH’s National Center for Advancing Translational Sciences (NCATS), a member of the Institute of Medicine’s Forum on Drug R&D and Translation, a member of the Advisory Board of Science Translational Medicine, a non-executive Director of Glenmark Pharmaceuticals, and an Advisor to or Board member of a dozen other companies and research organizations. His research has been published in Nature and Science, and profiled by Forbes magazine. The popular industry newsletter FiercePharma has named him one of the 25 most influential people in biopharma. He blogs about biomedical innovation on the Forbes and FasterCures websites. He received his MBA from Stanford University, and holds other graduate degrees in animal science and agricultural economics from the Paris Institute of Technology for Life, Food and Environmental Sciences and the University of California, Davis.
Peter C. Rowe, MD
Professor of Pediatrics, Johns Hopkins Children’s Center
Dr. Peter Rowe is a Professor of Pediatrics at the Johns Hopkins Children’s Center in Baltimore, Maryland. He graduated from the McMaster University Medical School, Hamilton, Ontario, Canada, in 1981. From 1981 to 1987, he was a resident, General Academic Pediatrics research fellow, and Chief Resident in Pediatrics at the Johns Hopkins Hospital. Between 1987 and 1991 he was a staff member at the Children’s Hospital of Eastern Ontario, Ottawa, Canada, and an Assistant Professor of Epidemiology and Community Medicine, and of Pediatrics.
Dr. Rowe returned to Johns Hopkins University in 1991. He has published over 60 peer-reviewed papers, 10 book chapters, and edited the 11th edition of the Harriet Lane Handbook. His clinical interests have been in the area of diagnostic dilemmas and complex chronic illness. He directed the Johns Hopkins Children’s Center Diagnostic Referral Clinic from 1991 to 1997. His early research interests were in the general area of clinical epidemiology in Pediatrics, but in the past 19 years his work has focused more exclusively on conditions characterized by chronic fatigue. His work first described the relationship between chronic fatigue syndrome (CFS) and treatable orthostatic intolerance syndromes, and first reported the association between Ehlers-Danlos syndrome and CFS. The research has been funded by the National Institutes of Health, the US Department of Defense, the CFIDS Association of America, and several smaller foundations, as well as by private philanthropy. He has directed the Chronic Fatigue Clinic at the Johns Hopkins Children’s Center since 1996, where he is the inaugural recipient of the Sunshine Natural Wellbeing Foundation Chair in Chronic Fatigue and Related Disorders.
Tomasz Sablinski, M.D., Ph.D.
Founder and CEO, Transparency Life Sciences; Managing Director, Auven Therapeutics
Tomasz Sablinski, M.D., Ph.D., is passionate about changing the paradigm of developing new drugs by converging modern information technology with drug development “know-how”, and exploiting an unlimited potential of “knowledge networking” to revolutionize drug research. He is a Founder and CEO of Transparency Life Sciences, the world’s first crowd-sourced drug development enterprise. Sablinski has been a Managing Director at Auven Therapeutics, (formerly Celtic) and Head of Celtic Therapeutic Development since 2008. Prior to joining Celtic he held positions of increasing responsibility in clinical development and medical affairs at Novartis Pharmaceuticals. He was a Vice President and Head of several therapeutic areas, including immunology and transplantation, GI, urology, bone and endocrinology. During his eleven years at Novartis he was based in the US, Switzerland, and for two years he was Head of Japanese-Global Development coordination. Prior to joining Novartis in 1997 Sablinski was Medical Director at Parexel, and served as a scientific advisor to several biotechnology companies developing biologics in areas of transplantation and autoimmune diseases. He joined pharmaceutical industry from Harvard Medical School, where he was an Instructor in Surgery from 1992 to 1997. He was a member of a Transplantation Biology Research Center team at Massachusetts General Hospital conducting pioneering work in transplantation tolerance and xenotransplantation. Prior to this he did translational research on novel biologic agents at the Brigham and Women’s Hospital. Sablinski is a board certified surgeon and his clinical work at Warsaw Medical School, Poland and Lahey Clinic, Burlington, MA concentrated on renal transplantation and general surgery. He authored and co-authored over 50 scientific papers and several book chapters. He is a member of The Transplantation Society since 1992. Sablinski received his MD and PhD degrees at Warsaw Medical School, Poland.
Terry Tyler, M.D.
Terry Tyler MD is a retired diagnostic radiologist. He started his outpatient radiology imaging center, Radiology & Diagnostic Imaging (RDI) in 1983. Innovation was the hallmark of the practice. He prioritized customer service and state-of-the-art imaging equipment. He brought advances in ultrasound, MRI, CT, PET, and new data imaging techniques usually only found at universities to a small Kentucky town.
Currently, Dr. Tyler is hoping to help bring innovation to ME/CFS research. Not only will ME/CFS research advances benefit his daughter who has suffered from CFS for 12 years, but it will also help all people with the disease and others with similar disorders.